November 10, 2010 - New CDC Report Indicates Type 2 Diabetes on the Rise… Diabetes Projected to affect up to 1 in 3 Americans by 2050 - Wound Management Technologies, Inc., (WNDM: OTCQB) a leader in advanced wound care solutions, is meeting the challenge of a rise in type 2 diabetes in the US, as chronicled by a new report by the Center for Disease Control (CDC). The report published in the October 22, 2010 journal Population Health Metrics recommends that proper diet and physical activity can prevent type 2 diabetes and reduce its complications, among the most severe of which are diabetic ulcers and amputations. Wound Management, exclusive worldwide licensee and distributor of CellerateRX® wound care powder and gel, further recommends that existing diabetic patients who suffer from moderate to heavily exudative wounds should ask their doctor whether CellerateRX® may be an effective treatment for them. CellerateRX® is the only activated Type 1 collagen-based product reimbursed by Medicare and has been shown to effectively manage diabetic ulcers.... Wound Management Technologies' Press Release -
Wednesday, November 10, 2010
Wound Management Technologies : CellerateRX® Effectively Manages Diabetic Ulcers…
November 10, 2010 - New CDC Report Indicates Type 2 Diabetes on the Rise… Diabetes Projected to affect up to 1 in 3 Americans by 2050 - Wound Management Technologies, Inc., (WNDM: OTCQB) a leader in advanced wound care solutions, is meeting the challenge of a rise in type 2 diabetes in the US, as chronicled by a new report by the Center for Disease Control (CDC). The report published in the October 22, 2010 journal Population Health Metrics recommends that proper diet and physical activity can prevent type 2 diabetes and reduce its complications, among the most severe of which are diabetic ulcers and amputations. Wound Management, exclusive worldwide licensee and distributor of CellerateRX® wound care powder and gel, further recommends that existing diabetic patients who suffer from moderate to heavily exudative wounds should ask their doctor whether CellerateRX® may be an effective treatment for them. CellerateRX® is the only activated Type 1 collagen-based product reimbursed by Medicare and has been shown to effectively manage diabetic ulcers.... Wound Management Technologies' Press Release -
